Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Michael L Zeckel"'
Autor:
James R. Woodworth, Michael L. Zeckel
This chapter seeks to provide an overview of clinically useful information regarding the pharmacokinetics, clinical uses, and safety profile of vancomycin. Vancomycin exhibits poor oral bioavailability. Following oral administration, only trace amoun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ca6168a610d58c03cc3b2b7d2217507
https://doi.org/10.1201/9781003067269-9
https://doi.org/10.1201/9781003067269-9
Autor:
Kenneth Hornbuckle, Chris Killian, Simon Voss, Arie Regev, Xiao Yan Yang, Yan Chen, Michael L. Zeckel
Publikováno v:
Drug Safety. 34:73-82
Routine surveillance of spontaneous reporting data and subsequent disproportionality analyses have indicated that the use of vancomycin might be associated with an increased risk of hepatic events.To conduct a meta-analysis of published randomized co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97fafb1622c0ee8ba68df6d7455b03b
https://doi.org/10.2165/11539560-000000000-00000
https://doi.org/10.2165/11539560-000000000-00000
Publikováno v:
Antimicrobial Agents and Chemotherapy. 44:1370-1374
The in vitro activity of LY333328 was evaluated for 1,479 nosocomial gram-positive pathogens isolated in 12 countries during 1997. LY333328 MICs at which 90% of the isolates tested were inhibited for Enterococcus faecalis ( n = 351), Enterococcus fae
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c9c1be17355b7db9abdbd65957a800f
https://doi.org/10.1128/aac.44.5.1370-1374.2000
https://doi.org/10.1128/aac.44.5.1370-1374.2000
Autor:
Michael L. Zeckel
Publikováno v:
The American Journal of Medicine. 92:S58-S64
Two controlled clinical trials compared loracarbef (LY163892 with amoxicillin/clavulanate or amoxicillin in the treatment of acute exacerbations of chronic bronchitis. Collectively, of 1,057 patients enrolled, 390 qualified for analysis: group 1 comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::932476b3c2d5ba25c7c0e90295a52c62
https://doi.org/10.1016/0002-9343(92)90609-f
https://doi.org/10.1016/0002-9343(92)90609-f
Autor:
Francis P. Tally, Claudio Carini, Michael L Zeckel, Frederick B. Oleson, Cindy L Berman, Margaret M Wasilewski, George L Drusano
Publikováno v:
Expert opinion on investigational drugs. 8(8)
The alarming increase in the incidence of Gram-positive infections, including those caused by resistant bacteria, has sparked renewed interest in novel antibiotics. One such agent is daptomycin, a novel lipopeptide antibiotic with proven bactericidal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5195e56c69c37e8d57696afa40d2c64
https://pubmed.ncbi.nlm.nih.gov/15992147
https://pubmed.ncbi.nlm.nih.gov/15992147
Autor:
Michael L Zeckel, Michael A Turik
Publikováno v:
Expert Opinion on Investigational Drugs. 4:889-891
New therapeutic options are required to address the issue of Gram-positive resistance which is currently emerging. Today, the glycopeptides vancomycin and teicoplanin are the clinician's last weapons against many serious pathogens, including MRSA (me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e537c07e09afc36527fb62ca574fb402
https://doi.org/10.1517/13543784.4.9.889
https://doi.org/10.1517/13543784.4.9.889
Autor:
Kristina M. Campanale, Philip W. Iversen, Carole J. Boylan, Thomas R. Parr, Diane L. Phillips, Michael L. Zeckel
Publikováno v:
Antimicrobial agents and chemotherapy. 47(5)
The pharmacokinetics and pharmacodynamics of oritavancin (LY333328), a glycopeptide antibiotic with concentration-dependent bactericidal activity against gram-positive pathogens, in a neutropenic-mouse thigh model of Staphylococcus aureus infection w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edafc4b0e37c027a5c037c77c284e983
https://pubmed.ncbi.nlm.nih.gov/12709343
https://pubmed.ncbi.nlm.nih.gov/12709343
Publikováno v:
Trends in microbiology. 5(6)
The incidence of infections caused by resistant Gram-positive pathogens is increasing, while emergence of vancomycin resistance is reducing the number of therapeutic options. New agents are being rapidly evaluated as candidates to replace vancomycin;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95e57b559c3bd1cf09194923b2f67cf6
https://pubmed.ncbi.nlm.nih.gov/9211645
https://pubmed.ncbi.nlm.nih.gov/9211645
Publikováno v:
Clinical therapeutics. 18(2)
Loracarbef, a beta-lactam antibiotic of the carbacephem class, is active in vitro against pathogens associated with acute maxillary sinusitis. To study the extent and duration of maxillary sinus fluid penetration after administration of loracarbef, 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a467ecdca7523cfaa5215778ad50ba30
https://pubmed.ncbi.nlm.nih.gov/8733988
https://pubmed.ncbi.nlm.nih.gov/8733988
Publikováno v:
Clinical therapeutics. 17(2)
Loracarbef is an oral synthetic beta-lactam antibiotic in the new carbacephem class. We conducted a multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of loracarbef 200 mg twice daily (BID) and 400 mg BID w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b069d58ad38eba388c3f5f3d25f8ef21
https://pubmed.ncbi.nlm.nih.gov/7614522
https://pubmed.ncbi.nlm.nih.gov/7614522